WO2013108056A1 - Fitocomposición para el tratamiento de dolores relacionados con enfermedades articulares - Google Patents
Fitocomposición para el tratamiento de dolores relacionados con enfermedades articulares Download PDFInfo
- Publication number
- WO2013108056A1 WO2013108056A1 PCT/IB2012/000051 IB2012000051W WO2013108056A1 WO 2013108056 A1 WO2013108056 A1 WO 2013108056A1 IB 2012000051 W IB2012000051 W IB 2012000051W WO 2013108056 A1 WO2013108056 A1 WO 2013108056A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- phytocomposition
- extracts
- pharmaceutical composition
- further characterized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Definitions
- the present invention is related to the techniques used in the Pharmaceutical Industry for obtaining and manufacturing natural medicines, and more particularly, it is related to a phytocomposition for the treatment of pains related to joint diseases.
- rheumatoid arthritis ⁇ chronic, recurrent and systemic disease that mainly affects the diarthodic joints that correspond to the extremities and which have the greatest movement.
- Arthritis occurs more frequently in women than in men, in a 3: 1 ratio, in which constitutional symptoms include malaise, fever and weight loss.
- DMARDs disease-modifying drugs
- TNF biological anti-tumor necrosis factor
- IL interleukin inhibitor
- biological agents such as chimeric monoclonal antibodies and recombinant fusion proteins, are used to increase the production of anti-inflammatory cytokines or to inhibit proinflammatory cytokines, observing a very good action and low toxicity.
- biological agents such as chimeric monoclonal antibodies and recombinant fusion proteins, are used to increase the production of anti-inflammatory cytokines or to inhibit proinflammatory cytokines, observing a very good action and low toxicity.
- their main disadvantage is that they have a considerably high cost.
- the "arnica” is a perennial herbaceous plant belonging to the family of
- Compositae It is useful to relieve all kinds of trauma and bruises, as well as muscular and rheumatic pain, among other uses. This plant has a moderate toxicity, so its use is recommended only externally.
- flavonoids asstragaloside, isoquercitrósido and quercetol-3-glucogalacturonic
- carotenes zeaxanthin
- essential oils caffeic, chlorogenic, thymol, floro !, polyacetylene compounds, arnidiol, faradiol, teraxaster, teraxaster, teraxaster) fixed oils (glycerides of palmitic, oleic and lauric acids), resin (containing cytisine and gallic acid), alkaloids (arnicine), acetylenic derivatives (betaine and choline), arnicolide A and sesquiterpenic lactone (helenaline and dihydrohelenaline
- flavonoids exert antispasmodic and hypotensive properties.
- Carotenes and manganese give it anti-neuralgic, anti-rheumatic, anti-inflammatory and antiequimotic action.
- Essential oils have an antibacterial and sedative nervous effect. It is known that sesquiterpenic lactose shows an anti-inflammatory effect, especially those with a-methylene-qp-lactonic structure. The biological effects of these substances are mediated through immunological processes. The most active of these is helenalin, which is due to the use of arnica against pain and inflammation.
- flavonoids hesperidósido, cirsimarina, diosmin, apigenina, luteolina
- diterpenic derivatives Rosmaridiphenol, carnosol, carnsolic acid, rosmanol, rosmadial, ursolic acid and amirin
- essential oils cineol, canfrene, camphor, borneol
- phenolic acids rosmarinic, caffeic, chlorogenic
- alkaloids rosmaricin
- mineral elements sodium, potassium, calcium, magnesium, iron, copper, zinc and manganese
- rosmarinic acid inhibits the activity of lipoxygenase in the cascade mechanism of arachidonic acid, so its anti-inflammatory effects may be due to the decrease in the formation of prostaglandins and leukotrienes and the induction of D-galactosamine, inhibiting the formation of peroxynitrite and resulting in the anti-inflammatory effect.
- the active compounds present in the "ginger” have activity on the biosynthesis of prostaglandins, in addition to effects on the 5-lipoxygenase arachidonate, which synthesizes leukotrienes.
- a ginger extract inhibits the activity of cyclooxygenase and lipoxygenase in the cascade mechanism of arachidonic acid, so it is considered that its anti-inflammatory effects may be due to the decrease in the formation of prostaglandins and leukotrienes. It also acts as a potent thromboxane synthetase inhibitor, raising prostacyclin levels and increasing prostaglandins E2 or F2a.
- gingerol which inhibits the edema of the rat leg induced by carrageenan by inhibiting the activity of cyclooxygenase
- gingerol has an effect Inhibitory in the biosynthesis of prostaglandins such as PG2, which is involved in inflammatory processes.
- boswellia has an analgesic and anti-inflammatory effect, comparable to non-steroidal anti-inflammatory drugs (NSAIDs).
- NSAIDs non-steroidal anti-inflammatory drugs
- the anti-inflammatory effect of boswellia resin is attributed to the presence of boswellic acids that inhibit two pro-inflammatory enzymes, 5-lipoxygenase and human leukocyte elastase (HLE).
- Boswellic acids increase the blood flow to the joints and restore the integrity of the vessels obstructed by spasms, constituting an appropriate therapy in cases of stiffness, pain and decreased joint strength due to arthritis.
- compositions that include among their components some of the above-mentioned plant species, although in combination with other plants.
- US Patent No. 5,494,668 describes a composition comprising extracts of Withania somn ⁇ fera, Boswellia serrata, Turmeric longa and Zingiber officinale; This composition is administered enterally, preferably, and is useful for treating rheumatoid arthritis and osteoarthritis.
- US Patent No. 6,534,086 describes a composition for the treatment of pain and inflammation caused by joint diseases, among other conditions, and which consists of a boswellic acid and a curcuminoid, and may also contain other compounds such as gingerol. , preferably derived from a botanical source.
- International Publication No. WO2010 / 068264 describes an oral administration formulation comprising herbal extracts of Withania somn ⁇ fera, Boswellia serrata, Turmeric longa and Zingiber officinale. This formulation is used to relieve symptoms associated with a cyclooxygenase, a pro-inflammatory cytosine or a pro-inflammatory enzyme, including rheumatoid arthritis and osteoarthritis.
- compositions that include phytocomposition and a pharmaceutically acceptable vehicle to significantly reduce pain related to joint diseases in patients suffering from them by administering a therapeutically safe and effective amount of said pharmaceutical composition
- the phytocomposition comprises:
- compositions comprising the aforementioned phytocomposition in combination with a pharmaceutically acceptable carrier, which is preferably administered topically in the form of lotion, emulsion, cream or gel.
- a pharmaceutically acceptable carrier which is preferably administered topically in the form of lotion, emulsion, cream or gel.
- This composition is used to treat muscular, arthritic and rheumatic pain caused by joint diseases in a patient.
- Figure 1 is a bar graph in which 'the results of decreased pain is to treat two groups of patients with joint diseases, wherein one group was treated with a fitocomposiissus containing only two plant extracts and Another group was treated with the pharmaceutical composition of the present invention.
- a phytocomposition has been developed that has a synergistic effect when used in the treatment to reduce the muscular, arthritic and rheumatic pains associated with joint diseases, since it provides analgesic effects, allowing the patient to reduce the pain of effective way.
- This phytocomposition was developed using as extracts Arnica montana (arnica), Rosmarinus officinalis (rosemary), Zingiber officinale (ginger) and Boswellia serrata (boswellia).
- a pharmaceutical composition comprising said phytocomposition and a pharmaceutically acceptable vehicle, which is administered topically to those patients suffering from pain caused by joint diseases.
- a therapeutically effective amount of said pharmaceutical composition to significantly reduce the pain caused by said joint diseases is described. It should be understood from what is described herein that a "therapeutically effective amount" refers to an amount necessary to achieve a selected result.
- a phytocomposition useful in the treatment of muscular, arthritic and rheumatic pain which comprises:
- the phytocomposition comprises:
- the phytocomposition of the present invention comprises:
- Extracts of these four species that are part of the phytocomposition of the present invention are selected from the group of alcoholic extracts, aqueous extracts or hydro-alcoholic extracts, preferably using hydro-alcoholic extracts in the specific embodiment of the present invention, that is, its preparation is from a mixture of water and an alcohol, wherein said extracts are obtained through the various procedures known in the prior art.
- a pharmaceutical composition comprising a therapeutically effective amount of said phytocomposition in combination with a pharmaceutically acceptable carrier, which is preferably administered topically.
- Said pharmaceutical composition has a pharmaceutical form that is selected from lotion, emulsion, cream or gel, being more preferably in the form of lotion.
- the use of the phytocomposition of the present invention in combination with a pharmaceutically acceptable carrier allows the preparation of the pharmaceutical composition useful in the treatment of muscular, arthritic and rheumatic pain caused by joint diseases in a mammal, particularly in humans.
- said joint diseases consisting of rheumatoid arthritis, osteoarthritis, fibromyalgia, gouty arthritis, psoriatic arthritis, lupus and juvenile arthritis.
- the pharmaceutical composition provides analgesic and anti-inflammatory effects, also allowing to reduce joint dysfunctionality by improving joint mobility, a circumstance that is characteristic in people with joint disorders.
- the pharmaceutical composition is used in patients suffering from joint diseases, wherein the treatment consists of administering to a patient, preferably topically, a therapeutically effective amount of a pharmaceutical composition that includes the phytocomposition of the present. invention as defined above.
- joint diseases where it is possible to use the composition are those that have been previously mentioned.
- VAS horizontal analogue scale
- the main inclusion criteria for the clinical study were: patients aged between 45 and 75 years, men or women, with a diagnosis of rheumatoid arthritis in hands and with pain equal to or greater than 5, in a horizontal VAS such as the one mentioned above. .
- the non-inclusion criteria were mainly patients with another inflammatory disease other than rheumatoid arthritis and people with steroid infiltration up to two months before entering the protocol.
- each patient in the first group received a bottle with 65 mL of lotion from a phytocomposition comprising Arnica montana extract and Rosmarinus officinalis extract, as well as excipient c.b.p. 100 mL
- each patient in the second group received a bottle with 65 mL of the phytocomposition lotion of the present invention, which was prepared as a lotion, as described in Example 1.
- the lotion was applied topically four times a day, every 6 hours, for 90 days. Of the total of the patients, 100% concluded the treatment.
- the phytocomposition for the treatment of muscular, arthritic and rheumatic pain of the present invention have been devised to assist in the treatment of joint diseases, and more specifically, in arthritis, helping to manifest improvement in the dysfunctionality of patients in an extremely effective way.
- the pharmaceutical composition of the present invention can be made innumerable modifications, such as the concentration of the 4 basic species that comprise it, as well as the pharmaceutical form that allows it to be administered to a patient, among others.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2014008476A MX347457B (es) | 2012-01-16 | 2012-01-16 | Fitocomposición para el tratamiento de dolores relacionados con enfermedades articulares. |
CN201280071495.6A CN104540513B (zh) | 2012-01-16 | 2012-01-16 | 用于治疗与关节疾病相关疼痛的植物组合物 |
US14/372,348 US9381221B2 (en) | 2012-01-16 | 2012-01-16 | Phytocomposition for the treatment of pain related to joint diseases |
PCT/IB2012/000051 WO2013108056A1 (es) | 2012-01-16 | 2012-01-16 | Fitocomposición para el tratamiento de dolores relacionados con enfermedades articulares |
BR112014017544-6A BR112014017544A2 (pt) | 2012-01-16 | 2012-01-16 | fitocomposição para o tratamento de dores relacionadas com doenças das articulações |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2012/000051 WO2013108056A1 (es) | 2012-01-16 | 2012-01-16 | Fitocomposición para el tratamiento de dolores relacionados con enfermedades articulares |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013108056A1 true WO2013108056A1 (es) | 2013-07-25 |
Family
ID=48798716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2012/000051 WO2013108056A1 (es) | 2012-01-16 | 2012-01-16 | Fitocomposición para el tratamiento de dolores relacionados con enfermedades articulares |
Country Status (5)
Country | Link |
---|---|
US (1) | US9381221B2 (es) |
CN (1) | CN104540513B (es) |
BR (1) | BR112014017544A2 (es) |
MX (1) | MX347457B (es) |
WO (1) | WO2013108056A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11413269B2 (en) * | 2015-09-03 | 2022-08-16 | Pathways Bioscience, Llc | Compositions for improved NRF2 activation and methods of their use |
CN107519465A (zh) * | 2017-09-02 | 2017-12-29 | 合肥今越制药有限公司 | 一种用于治疗肌肉、关节疼痛的药物 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1252074B (it) * | 1991-01-04 | 1995-05-29 | Giuseppe Mastronicola | Estratto idroalcolico di erbe e piante medicinali per la cura di: tendiniti-nevriti- sciatalgie-dolori reumatici, articolari, cervicali torcicolli. |
US5494668A (en) * | 1994-07-11 | 1996-02-27 | Patwardhan; Bhushan | Method of treating musculoskeletal disease and a novel composition therefor |
WO2002004003A2 (en) * | 2000-07-10 | 2002-01-17 | N.V. Nutricia | Composition for the treatment of osteoarthritis |
US6534086B1 (en) * | 2000-03-06 | 2003-03-18 | Metagenics, Inc. | Composition and method for treatment of inflammation and pain in mammals |
US6579543B1 (en) * | 2002-02-22 | 2003-06-17 | Jackie H. McClung | Composition for topical application to skin |
US20060115544A1 (en) * | 2004-12-01 | 2006-06-01 | Frank Steven R | Method and composition for the treatment of muscular-skeletal and related afflictions |
US20070154575A1 (en) * | 2005-10-26 | 2007-07-05 | Hiroshi Shimoda | Anti-inflammatory agent |
WO2007145655A1 (en) * | 2006-06-09 | 2007-12-21 | Guthy-Renker Corporation | Pain relief composition |
ES2314057T3 (es) * | 2001-04-05 | 2009-03-16 | New Chapter, Inc. | Composicion herbal antiinflamatoria. |
AU2009101061A4 (en) * | 2009-10-21 | 2010-02-25 | G & W Aust Pty Ltd | Herbal compositions and topical uses for relief of arthritic pain and joint inflammation |
WO2010068264A2 (en) * | 2008-12-11 | 2010-06-17 | Bio-Ved Pharmaceuticals, Inc. | Novel formulations to inhibit cyclooxygenase and pro-inflammatory cytokine mediated diseases |
US20110212193A1 (en) * | 2010-02-26 | 2011-09-01 | Urschel Michael J | Herbal Ointment for Musculoskeletal and Joint-Related Conditions |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5976547A (en) * | 1997-04-22 | 1999-11-02 | Niblick Pharmaceuticals, Inc. | Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery |
KR200326136Y1 (ko) * | 2003-05-30 | 2003-09-13 | 박노연 | 방문 |
-
2012
- 2012-01-16 CN CN201280071495.6A patent/CN104540513B/zh not_active Expired - Fee Related
- 2012-01-16 BR BR112014017544-6A patent/BR112014017544A2/pt not_active Application Discontinuation
- 2012-01-16 MX MX2014008476A patent/MX347457B/es active IP Right Grant
- 2012-01-16 US US14/372,348 patent/US9381221B2/en active Active
- 2012-01-16 WO PCT/IB2012/000051 patent/WO2013108056A1/es active Application Filing
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1252074B (it) * | 1991-01-04 | 1995-05-29 | Giuseppe Mastronicola | Estratto idroalcolico di erbe e piante medicinali per la cura di: tendiniti-nevriti- sciatalgie-dolori reumatici, articolari, cervicali torcicolli. |
US5494668A (en) * | 1994-07-11 | 1996-02-27 | Patwardhan; Bhushan | Method of treating musculoskeletal disease and a novel composition therefor |
US6534086B1 (en) * | 2000-03-06 | 2003-03-18 | Metagenics, Inc. | Composition and method for treatment of inflammation and pain in mammals |
WO2002004003A2 (en) * | 2000-07-10 | 2002-01-17 | N.V. Nutricia | Composition for the treatment of osteoarthritis |
ES2314057T3 (es) * | 2001-04-05 | 2009-03-16 | New Chapter, Inc. | Composicion herbal antiinflamatoria. |
US6579543B1 (en) * | 2002-02-22 | 2003-06-17 | Jackie H. McClung | Composition for topical application to skin |
US20060115544A1 (en) * | 2004-12-01 | 2006-06-01 | Frank Steven R | Method and composition for the treatment of muscular-skeletal and related afflictions |
US20070154575A1 (en) * | 2005-10-26 | 2007-07-05 | Hiroshi Shimoda | Anti-inflammatory agent |
WO2007145655A1 (en) * | 2006-06-09 | 2007-12-21 | Guthy-Renker Corporation | Pain relief composition |
WO2010068264A2 (en) * | 2008-12-11 | 2010-06-17 | Bio-Ved Pharmaceuticals, Inc. | Novel formulations to inhibit cyclooxygenase and pro-inflammatory cytokine mediated diseases |
AU2009101061A4 (en) * | 2009-10-21 | 2010-02-25 | G & W Aust Pty Ltd | Herbal compositions and topical uses for relief of arthritic pain and joint inflammation |
US20110212193A1 (en) * | 2010-02-26 | 2011-09-01 | Urschel Michael J | Herbal Ointment for Musculoskeletal and Joint-Related Conditions |
Also Published As
Publication number | Publication date |
---|---|
CN104540513B (zh) | 2019-04-05 |
US20150024075A1 (en) | 2015-01-22 |
CN104540513A (zh) | 2015-04-22 |
MX2014008476A (es) | 2014-10-14 |
BR112014017544A2 (pt) | 2017-06-13 |
MX347457B (es) | 2017-04-27 |
US9381221B2 (en) | 2016-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ortiz et al. | Isolation, identification and molecular docking as cyclooxygenase (COX) inhibitors of the main constituents of Matricaria chamomilla L. extract and its synergistic interaction with diclofenac on nociception and gastric damage in rats | |
ES2353868T3 (es) | Composiciones de curcuminoides que presentan una inhibición sinérgica de la expresión y/o de la actividad de la ciclooxigenasa-2. | |
Akram et al. | Traditional and modern management strategies for rheumatoid arthritis | |
CN108349867A (zh) | 用于抑制asc的表达、nlrp3的表达和/或nlrp3炎性复合体的形成的双醋瑞因或其类似物 | |
Rahnama et al. | The Effects of Zingiber Officinale R. On Primary Dysmenorrhea | |
ES2315662T3 (es) | Formulaciones para el tratamiento de afecciones artriticas. | |
US20180280464A1 (en) | Compositions and Methods for Pain Relief | |
CA2966325A1 (en) | Formulations containing pomegranate seed oil, rosa canina fruit oil and inula viscosa oleoresin or extract. | |
JP6966998B2 (ja) | 口腔、咽喉及び気道の障害の治療のための配合物 | |
Niempoog et al. | The efficacy of powdered ginger in osteoarthritis of the knee | |
Paulis et al. | Peironimev-Plus® in the treatment of chronic inflammation of tunica albuginea (Peyronie's disease). results of a controlled study | |
ITRM20060163A1 (it) | Composizione spray ad uso topico per il tratamento e la prevenzione delle infezioni labiali da herpes simplex | |
ES2394316T3 (es) | Composiciones farmac�uticas de Carapa Guianensis. | |
WO2013108056A1 (es) | Fitocomposición para el tratamiento de dolores relacionados con enfermedades articulares | |
Adhikari et al. | Evaluation of anti-inflammatory effect of beetroot extract in animal models | |
ES2674874T3 (es) | Composición antiinflamatoria | |
EP2149378B1 (en) | Topical formulations for the symptomatic treatment of musculoskeletal disorders | |
Gan et al. | Volatile Oil of Platycladus Orientalis (L.) Franco Leaves Exerts Strong Anti-inflammatory Effects via Inhibiting the IκB/NF-κB Pathway | |
EP3795146B1 (en) | Pain-relieving and anti-inflammatory composition for local use | |
Zhao et al. | Effect of oriental herbal prescription Guan‐Xin‐Er‐Hao on coronary flow in healthy volunteers and antiapoptosis on myocardial ischemia‐reperfusion in rat models | |
JAAFAR et al. | The Use of Pharmaceutical Preparation of Phytosome Lepidium Sativum Extract as Anti-diarrheal Induced by the Bacteria E. coli in Mice. | |
El-Agamy et al. | Protective role of panax gensing on fluvoxamine maleate induced structural changes in the submandibular salivary gland of rats | |
Maksimović | On Frankincense | |
ES2298087B1 (es) | Fitocomposicion para el tratamiento de enfermedades articulares. | |
EP3810108A1 (en) | Composition for use in the prevention and/or treatment of osteoarticular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12866211 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/008476 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14179296 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14372348 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014017544 Country of ref document: BR |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12866211 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 112014017544 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140716 |
|
ENP | Entry into the national phase |
Ref document number: 112014017544 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140716 |